(ELV) Elevance Health - Overview
Stock: Health Plans, Pharmacy Services, Administrative Services, Specialty Insurance
| Risk 5d forecast | |
|---|---|
| Volatility | 30.1% |
| Relative Tail Risk | -7.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -23.17 |
| Character TTM | |
|---|---|
| Beta | 0.280 |
| Beta Downside | 0.058 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.38% |
| CAGR/Max DD | -0.21 |
EPS (Earnings per Share)
Revenue
Description: ELV Elevance Health March 02, 2026
Elevance Health Inc. (ELV) is a U.S. health-benefits company operating through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a broad suite of products-including commercial, Medicare, Medicaid, and federal employee plans-alongside fee-based administrative services, specialty insurance, and a full pharmacy-services platform that covers home delivery, specialty drugs, and infusion therapy.
In its most recent fiscal year (2024), Elevance reported revenue of $147 billion, a 5.2% year-over-year increase, and net income of $5.2 billion, driven by a 3.8% rise in total enrollment to 110 million members. The CarelonRx segment saw a 7% growth in pharmacy-benefit revenue, reflecting strong demand for specialty and injectable therapies.
The managed-care sector is being propelled by an aging U.S. population-Medicare Advantage enrollment is expected to grow at a 9% CAGR through 2028-and by continued pressure on drug pricing, prompting insurers to expand pharmacy-benefit management and rebate-administration capabilities. Additionally, inflationary health-care cost pressures are encouraging providers to adopt virtual-care and utilization-management solutions, areas where Elevance’s HealthOS platform offers a competitive edge.
For a deeper dive into Elevance’s valuation metrics, you might explore ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 5.66b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.28 > 1.0 |
| NWC/Revenue: 2.39% < 20% (prev 11.32%; Δ -8.92% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.29b > Net Income 5.66b |
| Net Debt (23.74b) to EBITDA (9.66b): 2.46 < 3 |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.8m) vs 12m ago -4.02% < -2% |
| Gross Margin: 25.56% > 18% (prev 0.28%; Δ 2528 % > 0.5%) |
| Asset Turnover: 167.1% > 50% (prev 151.3%; Δ 15.80% > 0%) |
| Interest Coverage Ratio: 5.79 > 6 (EBITDA TTM 9.66b / Interest Expense TTM 1.40b) |
Altman Z'' 2.14
| A: 0.04 (Total Current Assets 24.73b - Total Current Liabilities 19.96b) / Total Assets 121.49b |
| B: 0.29 (Retained Earnings 35.39b / Total Assets 121.49b) |
| C: 0.07 (EBIT TTM 8.11b / Avg Total Assets 119.19b) |
| D: 0.45 (Book Value of Equity 34.94b / Total Liabilities 77.47b) |
| Altman-Z'' Score: 2.14 = BBB |
Beneish M -2.80
| DSRI: 0.71 (Receivables 15.23b/19.07b, Revenue 199.12b/176.81b) |
| GMI: 1.09 (GM 25.56% / 27.85%) |
| AQI: 1.48 (AQ_t 0.75 / AQ_t-1 0.51) |
| SGI: 1.13 (Revenue 199.12b / 176.81b) |
| TATA: 0.01 (NI 5.66b - CFO 4.29b) / TA 121.49b) |
| Beneish M-Score: -2.80 (Cap -4..+1) = A |
What is the price of ELV shares?
Over the past week, the price has changed by -4.73%, over one month by -6.39%, over three months by -2.44% and over the past year by -17.52%.
Is ELV a buy, sell or hold?
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 387.9 | 21.2% |
| Analysts Target Price | 387.9 | 21.2% |
ELV Fundamental Data Overview February 28, 2026
P/E Forward = 10.9529
P/S = 0.3581
P/B = 1.7523
P/EG = 0.8759
Revenue TTM = 199.12b USD
EBIT TTM = 8.11b USD
EBITDA TTM = 9.66b USD
Long Term Debt = 30.80b USD (from longTermDebt, last quarter)
Short Term Debt = 1.38b USD (from shortTermDebt, last quarter)
Debt = 33.23b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.74b USD (from netDebt column, last quarter)
Enterprise Value = 95.04b USD (71.30b + Debt 33.23b - CCE 9.49b)
Interest Coverage Ratio = 5.79 (Ebit TTM 8.11b / Interest Expense TTM 1.40b)
EV/FCF = 29.94x (Enterprise Value 95.04b / FCF TTM 3.17b)
FCF Yield = 3.34% (FCF TTM 3.17b / Enterprise Value 95.04b)
FCF Margin = 1.59% (FCF TTM 3.17b / Revenue TTM 199.12b)
Net Margin = 2.84% (Net Income TTM 5.66b / Revenue TTM 199.12b)
Gross Margin = 25.56% ((Revenue TTM 199.12b - Cost of Revenue TTM 148.22b) / Revenue TTM)
Gross Margin QoQ = 23.48% (prev 24.79%)
Tobins Q-Ratio = 0.78 (Enterprise Value 95.04b / Total Assets 121.49b)
Interest Expense / Debt = 1.10% (Interest Expense 366.0m / Debt 33.23b)
Taxrate = 15.63% (1.05b / 6.71b)
NOPAT = 6.84b (EBIT 8.11b * (1 - 15.63%))
Current Ratio = 1.24 (Total Current Assets 24.73b / Total Current Liabilities 19.96b)
Debt / Equity = 0.76 (Debt 33.23b / totalStockholderEquity, last quarter 43.88b)
Debt / EBITDA = 2.46 (Net Debt 23.74b / EBITDA 9.66b)
Debt / FCF = 7.48 (Net Debt 23.74b / FCF TTM 3.17b)
Total Stockholder Equity = 43.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.75% (Net Income 5.66b / Total Assets 121.49b)
RoE = 13.01% (Net Income TTM 5.66b / Total Stockholder Equity 43.52b)
RoCE = 10.92% (EBIT 8.11b / Capital Employed (Equity 43.52b + L.T.Debt 30.80b))
RoIC = 9.17% (NOPAT 6.84b / Invested Capital 74.60b)
WACC = 5.04% (E(71.30b)/V(104.53b) * Re(6.95%) + D(33.23b)/V(104.53b) * Rd(1.10%) * (1-Tc(0.16)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.01%
[DCF] Terminal Value 85.07% ; FCFF base≈3.73b ; Y1≈3.31b ; Y5≈2.77b
[DCF] Fair Price = 272.5 (EV 83.89b - Net Debt 23.74b = Equity 60.15b / Shares 220.7m; r=5.90% [WACC]; 5y FCF grow -13.66% → 2.90% )
EPS Correlation: -31.46 | EPS CAGR: -21.49% | SUE: 0.36 | # QB: 0
Revenue Correlation: 96.17 | Revenue CAGR: 7.38% | SUE: 1.69 | # QB: 6
EPS next Quarter (2026-06-30): EPS=6.69 | Chg7d=-0.070 | Chg30d=-1.183 | Revisions Net=-12 | Analysts=19
EPS current Year (2026-12-31): EPS=26.05 | Chg7d=-0.021 | Chg30d=-0.836 | Revisions Net=-12 | Growth EPS=-14.0% | Growth Revenue=-1.4%
EPS next Year (2027-12-31): EPS=29.56 | Chg7d=-0.056 | Chg30d=-1.658 | Revisions Net=-9 | Growth EPS=+13.5% | Growth Revenue=+2.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 12 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.1% (Discount Rate 7.9% - Earnings Yield 7.8%)
[Growth] Growth Spread = -1.8% (Analyst -1.6% - Implied 0.1%)